|
Hier einige Infos zu der Aktionärsversammlung vom 25.6.2003. Die Anträge von Viragen wurden alle genehmigt: ANNOUNCEMENT - Notice of Special Meeting of Stockholders INVESTOR RELATIONS CONTACT: Communications Douglas Calder, Director of Communications (954) 233-8746 - Fax (954) 233-1414 E-mail: dcalder@viragen.com Viragen held a special meeting of stockholders at the Renaissance Plantation Hotel located at 1230 Pine Island Road, Plantation, Florida, on Wednesday, June 25, 2003 at 2:00 p.m. (EDT) As noted in the proxy, stockholders of record at the close of business May 27, 2003 were entitled to vote to authorize certain equity financings as well as to approve a proposal to increase the number of authorized shares from 250 million to 700 million. The following items were approved by stockholders: Report of Elections 1. Increase the Number of Authorized Shares - Stockholders approved of increasing the number of authorized shares of common stock from 250 million to 700 million. 2. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen received gross proceeds of $2,476,050 through the sale if its convertible debentures, common stock and common stock purchase warrants to 5 institutional investors. 3. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen received gross proceeds of $3,758,132 through the sale if its convertible debentures and common stock purchase warrants to 4 institutional investors. 4. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen has the right to require an investor to purchase up to $12,000,000 in shares of Viragen common stock. Chairman`s Comments Chairman Carl N. Singer stated, "Our Board has determined that the approval of these measures provides Viragen the flexibility to execute its long-range business plan. With the approval of these measures, we expect to have access to our recently announced $12 million equity line of credit, subject to SEC clearance." "We are concerned about potential dilution, so we intend to draw upon the equity line only as needed to fund our operations and progress our commercial and scientific programs. We have based our request for the increased authorization on a set of assumptions which provides for unexpected events and/or opportunities, but our intent is to minimize the use of authorized but unissued shares." "While the equity line should be capable of providing needed funding, we will continue to seek strategic partners and new investors which could reduce the number of equity transactions needed to fund operations. Growth and expansion of our commercial activities could also diminish our reliance upon equity transactions to fund our business plan. In addition, management continues to aggressively contain costs, direct resources to priority programs and work towards building stockholder value. We appreciate our stockholders` continued support." Gruß Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (26.06.03 18:13:05) |
| Beitrag: | 27 von 128 (ID:9896138) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |